OXFORD, England, March 18, 2020 /CNW/ -- After more than one week of evidence, a federal jury in Delaware found in favour of Oxford Nanopore and invalidated all four patents asserted by Pacific Biosciences ("PacBio") in this litigation.
This outcome follows positive outcomes for Oxford Nanopore in previous proceedings.
Dr Gordon Sanghera, CEO of Oxford Nanopore, said: "We are pleased that the jury recognized that it is Oxford Nanopore, with the help of our collaborators across the globe and as part of the thriving nanopore community of users, who are the true innovators in the field of nanopore sequencing."
Dr. Sanghera added: "We will continue to deliver innovative sequencing technology to our customers, who are using the technology to make a profound, positive impact on society. "
A full press release from Oxford Nanopore can be found at https://nanoporetech.com/about-us/news/novel-coronavirus-covid-19-information-and-updates.
SOURCE Oxford Nanopore Technologies
For further information: Zoe McDougall, [email protected], 07973792520